FINOTTI, Alessia
 Distribuzione geografica
Continente #
NA - Nord America 16.478
AS - Asia 10.769
EU - Europa 8.349
SA - Sud America 1.784
AF - Africa 248
OC - Oceania 47
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 1
Totale 37.680
Nazione #
US - Stati Uniti d'America 16.063
SG - Singapore 4.004
CN - Cina 2.947
FI - Finlandia 2.180
IT - Italia 1.650
BR - Brasile 1.428
VN - Vietnam 1.091
PL - Polonia 1.088
HK - Hong Kong 860
DE - Germania 854
UA - Ucraina 589
GB - Regno Unito 516
TR - Turchia 416
FR - Francia 400
SE - Svezia 329
JP - Giappone 307
RU - Federazione Russa 257
IN - India 228
ID - Indonesia 227
CA - Canada 201
MX - Messico 153
AR - Argentina 133
BD - Bangladesh 132
NL - Olanda 129
ZA - Sudafrica 90
IQ - Iraq 82
ES - Italia 69
PK - Pakistan 65
EC - Ecuador 51
IR - Iran 51
CO - Colombia 49
VE - Venezuela 44
UZ - Uzbekistan 43
BE - Belgio 42
PH - Filippine 39
MA - Marocco 38
AT - Austria 34
AU - Australia 34
SA - Arabia Saudita 34
LT - Lituania 32
CZ - Repubblica Ceca 31
MY - Malesia 31
GR - Grecia 30
CL - Cile 28
KR - Corea 26
AE - Emirati Arabi Uniti 25
EG - Egitto 22
KE - Kenya 20
RO - Romania 20
IE - Irlanda 18
PY - Paraguay 18
TH - Thailandia 17
TN - Tunisia 17
CH - Svizzera 16
AZ - Azerbaigian 15
DZ - Algeria 15
IL - Israele 15
JO - Giordania 14
PT - Portogallo 14
NP - Nepal 13
UY - Uruguay 13
ET - Etiopia 12
PE - Perù 12
KG - Kirghizistan 11
NZ - Nuova Zelanda 11
TW - Taiwan 11
JM - Giamaica 10
CR - Costa Rica 9
KZ - Kazakistan 9
LB - Libano 9
PA - Panama 9
DO - Repubblica Dominicana 8
BO - Bolivia 7
RS - Serbia 7
LY - Libia 6
AO - Angola 5
BG - Bulgaria 5
BH - Bahrain 5
HN - Honduras 5
NI - Nicaragua 5
OM - Oman 5
PS - Palestinian Territory 5
SI - Slovenia 5
AL - Albania 4
DK - Danimarca 4
GE - Georgia 4
HR - Croazia 4
KW - Kuwait 4
LK - Sri Lanka 4
NO - Norvegia 4
YE - Yemen 4
BB - Barbados 3
DM - Dominica 3
HU - Ungheria 3
LV - Lettonia 3
SN - Senegal 3
TT - Trinidad e Tobago 3
CI - Costa d'Avorio 2
CY - Cipro 2
EE - Estonia 2
Totale 37.624
Città #
Singapore 2.423
Ashburn 2.252
Helsinki 1.965
San Jose 1.166
Woodbridge 1.128
Beijing 1.127
Fairfield 1.122
Warsaw 1.075
Hong Kong 837
Santa Clara 799
Chandler 775
Ann Arbor 772
Houston 693
Jacksonville 653
Wilmington 468
Seattle 466
Ferrara 445
Cambridge 339
Ho Chi Minh City 339
Los Angeles 295
Tokyo 290
New York 276
Dallas 265
Hanoi 252
Nanjing 249
Munich 237
Council Bluffs 234
Izmir 228
Lauterbourg 205
Princeton 199
Jakarta 176
Shanghai 140
Addison 130
Boardman 128
Bologna 118
Milan 115
São Paulo 115
Bremen 111
Orem 94
Redwood City 93
San Diego 90
London 87
Mexico City 85
Shenyang 85
Verona 84
Turku 81
Hefei 67
Brooklyn 64
Rio de Janeiro 62
Montreal 61
Nanchang 61
Chicago 60
Rome 60
Falls Church 58
Denver 56
The Dalles 54
Chennai 53
Da Nang 53
Toronto 50
Frankfurt am Main 48
Hebei 48
Moscow 48
Dong Ket 47
Stockholm 46
Buffalo 44
Johannesburg 44
San Francisco 44
Dearborn 43
Changsha 42
Atlanta 41
Hangzhou 41
Guangzhou 40
Haiphong 38
Jiaxing 38
Amsterdam 37
Boston 37
Manchester 37
Tashkent 37
Brussels 35
Tianjin 35
Jinan 34
Mountain View 33
Phoenix 33
Curitiba 32
Poplar 32
Zhengzhou 32
Norwalk 31
Auburn Hills 30
Baghdad 30
Columbus 28
Dhaka 28
Brasília 27
Ankara 26
Nuremberg 26
Washington 25
Belo Horizonte 24
Biên Hòa 24
Des Moines 24
Falkenstein 23
Caracas 20
Totale 25.497
Nome #
509 Cystic fibrosis transmembrane conductance regulator positively regulates angiotensin-converting enzyme 2 expression and SARS-CoV-2 viral entry into airway epithelial cells: Implications for patients with cystic fibrosis 2.014
An Aγ-globin G->A gene polymorphism associated with β(0)39 thalassemia globin gene and high fetal hemoglobin production 413
A validated cellular biobank for β-thalassemia 412
Transient Receptor Potential Ankyrin 1 Channels Modulate Inflammatory Response in Respiratory Cells from Patients with Cystic Fibrosis 399
BCL11A mRNA targeting by miR-210: A possible network regulating γ-globin gene expression 375
Ground state naïve pluripotent stem cells and CRISPR/Cas9 gene correction for β-thalassemia 363
TREATMENT OF BETA-THALASSEMIA PATIENTS WITH RAPAMYCIN (SIROLIMUS): FROM PRE-CLINICAL RESERCH TO A CLINICAL TRIAL 345
A validated THALAMOSS cellular biobank for β-thalassemia 331
Changes in hemoglobin profile reflect autologous blood transfusion misuse in sports 301
Development and characterization of K562 cell clones expressing BCL11A-XL: Decreased hemoglobin production with fetal hemoglobin inducers and its rescue with mithramycin 296
Generation and characterization of a transgenic mouse carrying a functional human β-globin gene with the IVSI-6 thalassemia mutation 295
The (A)gamma(+25 G -> A) polymorphism is associated with high HbF production leading to a decrease in binding activity of the LYAR transcription factor to the (A)gamma-globin gene in beta-thalassemia patients 292
A Novel Frameshift Mutation (+A) at Codon 18 of the beta-Globin Gene Associated with High Persistence of Fetal Hemoglobin Phenotype and deltabeta-Thalassemia 271
Erythroid induction of K562 cells treated with mithramycin is associated with inhibition of raptor gene transcription and mammalian target of rapamycin complex 1 (mTORC1) functions 270
Differential Effects of Angelicin Analogues on NF-kB Activity and IL-8 Gene Expression in Cystic Fibrosis IB3-1 Cells 270
SPR-based non-invasive prenatal testing for fetal sex determination 253
An antisense peptide nucleic acid against Pseudomonas aeruginosa inhibiting bacterial-induced inflammatory responses in the cystic fibrosis IB3-1 cellular model system 243
Possible detection of Autologous Blood Transfusion (ABT) based on circulating plasma microRNAs involved in erythroid differentiation and fetal hemoglobin induction 240
Impiego di strategie di microRNA targeting combinate a trattamenti con composti di origine naturale ad attività antiproliferativa e pro-apoptotica: studio dell’effetto antitumorale in-vitro su modelli cellulari di carcinoma del colon-retto, di glioblastoma e di carcinoma mammario (NaturalMiR-Combo)” 238
A novel and efficient protocol for Surface Plasmon Resonance based detection of four β-thalassemia point mutations in blood samples and salivary swabs 236
Y-chromosome identification in circulating cell-free fetal DNA using surface plasmon resonance 235
High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222 234
A peptide nucleic acid against microrna miR-145-5p enhances the expression of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Calu-3 Cells 234
Altered erythroid-related miRNA levels as a possible novel biomarker for detection of autologous blood transfusion misuse in sport 234
Isothermal circular-strand-displacement polymerization of DNA and microRNA in digital microfluidic devices 230
Binding of hybrid molecules containing pyrrolo [2,1-c][1,4]benzodiazepine (PBD) and oligopyrrole carriers to the human immunodeficiency type 1 virus TAR-RNA 227
MicroRNA miR-93-5p regulates expression of IL-8 and VEGF in neuroblastoma SK-N-AS cells 226
Corilagin Induces High Levels of Apoptosis in the Temozolomide-Resistant T98G Glioma Cell Line 221
Increase of microRNA-210, decrease of raptor gene expression and alteration of mammalian target of rapamycin regulated proteins following mithramycin treatment of human erythroid cells 220
A liquid biopsy model: Circulating miRNA levels in mice bearing colorectal carcinoma tumor xenografts 220
SPR-based biosensor for non-invasive prenatal diagnosis of Y-chromosome 220
A Saccharomyces cerevisiae model suitable for screening of correctors of stop-codon mutations 219
Peptide nucleic acids targeting β-globin mRNAs selectively inhibit hemoglobin production in murine erythroleukemia cells 219
Therapy for Cystic Fibrosis Caused by Nonsense Mutations 217
Induction of apoptosis of human glioma cell lines: Effects of combined treatment with corilagin and temozolomide 217
Development of K562 cell clones expressing beta-globin mRNA carrying the beta039 thalassemia mutation for the screening of correctors of stop codon mutations 212
Chemical-Induced Read-Through at Premature Termination Codons Determined by a Rapid Dual-Fluorescence System Based on S. cerevisiae 212
Epigenetic changes as a common trigger of muscle weakness in congenital myopathies 211
High levels of apoptosis induced in human glioma cell lines by combined treatment with antagomiR PNAs and pre-miRNA molecules 211
Combining gene therapy with fetal hemoglobin induction on erythroid precursor cells from β039 and IVS-I-110 thalassemia patients 209
AGENTI TRASFETTANTI PER ACIDI PEPTIDO-NUCLEICI 203
Regulation of IL-8 gene expression in gliomas by microRNAs 202
Digital microfluidic devices for isothermal circular strand displacement polymerization of microRNAs 200
The multicenter THALAMOSS cellular Biobank for β-Thalassemia 200
Complexation to cationic microspheres of double-stranded peptide nucleic acid-DNA chimeras exhibiting decoy activity 200
miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma 194
Antiproliferative and Erythroid Differentiation Activities of Cedrus libani Seed Extracts against K562 Human Chronic Myelogenus Leukemia Cells 193
Regulation of IL-8 gene expression in gliomas by microRNA miR-93 192
New insights into the Shwachman-Diamond Syndrome-related haematological disorder: Hyper-activation of mTOR and STAT3 in leukocytes 190
Peptide nucleic acids (PNA)-DNA chimeras targeting transcription factors as a tool to modify gene expression 189
Development and characterization of K562 cell clones expressing at high levels BCL11A: induction of erythroid differentiation by mithramycin 188
Generation and molecular characterization of a transgenic mouse line carrying a mutated human IVS-I-6 thalassemia beta-globin gene 185
Alteration of microRNA biological activity with peptide nucleic acid 185
Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells 185
Development of microRNA based protocols for detection of autologous blood transfusion in sport 185
Development and characterization of cellular biosensors for HTS of erythroid differentiation inducers targeting the transcriptional activity of γ-globin and β-globin gene promoters 185
Cellular biosensors for the identification of fetal hemoglobin inducers 184
Surface plasmon resonance based analysis of the binding of LYAR protein to the rs368698783 (G>A) polymorphic Aγ-globin gene sequences mutated in β-thalassemia 183
Biological evaluation of psoralen derivatives as inhibitors of NF-κB/DNA interaction: molecular modeling, 3D-QSAR, EMSA assays and inhibition of IL-8 gene expression 183
Double effects of mithramycin during induction of fetal hemoglobin: down regulation of BCL11A gene transcription and inhibition of the binding of the BCL11A transcriptional complex to the -globin gene promoter 182
Demonstrating specificity of bioactive peptide nucleic acids (PNAs) targeting microRNAs for practical laboratory classes of applied biochemistry and pharmacology 181
Expression of γ-globin genes in β-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin) 180
Structural and Functional Insights on an Uncharacterized Aγ-Globin-Gene Polymorphism Present in Four β(0)-Thalassemia Families with High Fetal Hemoglobin Levels 179
Production of β-globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous β039 thalassemia patients 178
PCR detection of segmented filamentous bacteria in the terminal ileum of patients with ulcerative colitis 176
A PNA-based masking strategy for CFTR upregulation by targeting miR-145-5p binding sites of CFTR mRNA 173
Structural characterization of promoter sequences of the gene coding human PKI55 protein, a protein kinase C inhibitor 172
Development and characterization of cellular biosensors for HTS of erythroid differentiation inducers targeting the transcriptional activity of gamma-globin and beta-globin gene promoters 172
miRNA therapeutics: delivery and biological activity of peptide nucleic acids targeting miRNAs 171
Development and molecular characterization of transgenic mice for beta-thalassemia 171
Efficient Delivery of MicroRNA and AntimiRNA Molecules Using an Argininocalix[4]arene Macrocycle 171
Constitutive systemic inflammation in Shwachman-Diamond Syndrome 170
PNAs targeting BCL11A at the miR-210 binding sites down-regulate BCL11A and up-regulate gamma-globin mRNA 169
A peptide nucleic acid targeting the acpP gene of Pseudomonas aeruginosa inhibits bacterial induced biological alterations in cystic fibrosis cells 169
A distinctive microrna (Mirna) signature in the blood of colorectal cancer (crc) patients at surgery 169
A peptide nucleic acid (PNA) masking the miR-145-5p binding site of the 3’UTR of the cystic fibrosis transmembrane conductance regulator (CFTR) mRNA enhances CFTR expression in Calu-3 cells 168
Modulation of the Biological Activity of microRNA-210 with Peptide Nucleic Acids (PNAs) 166
A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs 163
A Peptide-Nucleic Acid Targeting miR-335-5p Enhances Expression of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene with the Possible Involvement of the CFTR Scaffolding Protein NHERF1 162
Effects of Tobramycin activity on premature termination codons and interleukin 8 gene expression 161
Synergistic effects of the combined treatment of U251 and T98G glioma cells with an anti-tubulin tetrahydrothieno[2,3-c]pyridine derivative and a peptide nucleic acid targeting miR-221-3p 160
Bovine serum amine oxidase and spermine cause apoptosis in cancer cells detected by flow cytometry, real time RT-PCR and proteomic analyses 159
Analysis of the miRNome as a possible tool for the detection of autologous blood transfusion misuse in sport 159
Involvement of miRNA in erythroid differentiation 154
Targeting microRNAs involved in human diseases: A novel approach for modification of gene expression and drug development 154
INTRACELLULAR CALCIUM MOBILIZATION AND THE INFLAMMATORY RESPONSE IN CF BRONCHIAL EPITHELIAL CELLS 154
Synthesis and biological evaluation of new antitubulin agents containing 2-(30,40,50-trimethoxyanilino)-3,6-disubstituted-4,5,6,7-tetrahydrothieno[2,3-c]pyridine Scaffold 154
Real-time multiplex analysis of four beta-thalassemia mutations employing surface plasmon resonance and biosensor technology 153
Antiproliferative and erythroid differentiation of piperazine and triphenyl derivatives against k-562 human chronic myelogenous leukemia. 153
Recent trends for novel options in experimental biological therapy of β-thalassemia 153
AGENTI TRASFETTANTI PER microRNA E antagomiRNA 153
Circulating microRNAs and liquid biopsy: murine xenograft models for technical validation of clinical protocols 153
Pro‑apoptotic activity of novel synthetic isoxazole derivatives exhibiting inhibitory activity against tumor cell growth in vitro 153
Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221. 152
Effects of Sirolimus treatment on patients with β-Thalassemia: Lymphocyte immunophenotype and biological activity of memory CD4+ and CD8+ T cells 151
Targeting the miR-221/miR-222 cluster in cancer therapy 151
Acidi peptido-nucleici (PNA) per il Genome Editing in β-talassemia: correzione sito-specifica della mutazione β°39 151
In vitro induction of interleukin-8 by SARS-CoV-2 Spike protein is inhibited in bronchial epithelial IB3-1 cells by a miR-93-5p agomiR 151
Efficient cell penetration and delivery of peptide nucleic acids by an argininocalix[4]arene 150
A personalized medicine approach for beta-thalassemia patients: testing sirolimus in a first pilot clinical trial (sirthalaclin) 149
Totale 22.581
Categoria #
all - tutte 161.800
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 5.675
Totale 167.475


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021808 0 0 0 0 0 0 0 0 0 0 514 294
2021/20222.113 226 179 129 93 138 107 141 96 95 170 182 557
2022/20231.959 230 191 41 240 322 224 125 179 205 16 106 80
2023/20241.494 84 182 63 42 188 251 121 86 24 28 75 350
2024/20255.554 181 152 495 289 598 431 205 234 934 697 720 618
2025/202616.251 1.505 631 1.169 1.827 2.245 1.016 1.823 941 3.336 1.712 46 0
Totale 38.331